remdesivir

Remdesivir (GS-5734) is a nucleoside analog, a broad-spectrum antiviral compound that exerts its activity by inhibiting the RNA-dependent RNA polymerase of viruses. Remdesivir is active against Ebola, SARS, and MERS viruses, and is potentially therapeutic against COVID-19.

Anti-virus agent 1 (compound 4i), a phosphoramidate prodrug of GS-5734, exhibits potent antiviral efficacy and is primarily utilized in coronavirus and Ebola virus (EBOV) research.

Remdesivir de(ethylbutyl 2-aminopropanoate) is a recognized impurity in Remdesivir, a nucleoside analog demonstrating potent antiviral efficacy. It exhibits EC50 values of 74 nM against SARS-CoV and MERS-CoV in human airway epithelial (HAE) cells, and 30 nM against murine hepatitis virus in delayed brain tumor cells. Notably effective in vitro against SARS-CoV-2 (COVID-19) infection, Remdesivir has garnered attention for its application in controlling the spread of the virus, as supported by references [1] [2].

Remdesivir, also known as GS-5734, is a prodrug form of the antiviral nucleoside analog GS-44152. Remdesivir is a broad spectrum anti-viral drug that has shown to inhibit SARS-CoV-2, in vitro and in vivo. Efficacy of remdesivir against Ebola virus has been demonstrated. Remdesivir inhibits SARS-CoV-2 replication, reduces viral load, and exerts protective effects in SARS-CoV-2 infected animals. Remdesivir also reduces the pathological process, alleviates mild symptoms, and improves pulmonary lesions in SARS-CoV-2-infecetd animals. Remdesivir has been used as a compassionate drug for treating COVID-19 patients. *******WARNING****** Our product remdesivir is a pure chemical solid powder which is only for laboratory research use, NOT FOR HUMAN OR PATIENT USE

Remdesivir nucleoside monophosphate, a metabolite of Remdesivir, is a potent antiviral compound with nucleoside analogue characteristics. It exhibits effective antiviral activity against both SARS-CoV and MERS-CoV.

Remdesivir-D5 is a deuterium labeled Remdesivir. Remdesivir is a nucleoside analogue, with effective antiviral activity.

Remdesivir Impurity 5-d5 is a deuterated compound of Remdesivir Impurity 5.

Remdesivir O-desphosphate acetonide impurity is a contaminant found in Remdesivir (GS-5734), a nucleoside analogue recognized for its potent antiviral properties, particularly inhibiting SARS-CoV-2 (COVID-19) infection in vitro.

Remdesivir-d4 is a deuterated compound of Remdesivir. Remdesivir has a CAS number of 1809249-37-3. Remdesivir is a nucleoside analogue, with effective antiviral activity( EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells)

GS-443902 trisodium (GS-441524 triphosphate trisodium), the active triphosphate metabolite of Remdesivir (GS-5734), serves as a potent inhibitor of viral RNA-dependent RNA-polymerases (RdRp), displaying inhibitory concentrations (IC50) of 1.1 μM for RSV RdRp and 5 μM for HCV RdRp.

GS-441524 treatment of cats with naturally occurring feline infectious peritonitis.

Simeprevir (TMC435) is a potent HCV NS3 4A protease inhibitor, and inhibits HCV replication with EC50 of 8 nM.

GS-704277, an alanine metabolite derived from Remdesivir, a nucleoside analogue acknowledged for its potent antiviral efficacy, demonstrates remarkable effectiveness in vitro for the management of SARS-CoV-2 (COVID-19) infection[1][2].

BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase (RdRp) inhibitor, is effective orally and can inhibit various SARS-CoV-2 variants. It exhibits EC 50 values of 0.62 µM for SARS-CoV-2 and 0.14 µM for HCoV-229E, demonstrating potent anti-pancoronavirus activity at submicromolar concentrations. Additionally, BPR3P0128 displays synergistic antiviral effects when used in combination with Remdesivir [1].

GS-441524tris-isobutyryl ester is a prodrug form of the antiviral nucleoside analog and remdesivir metabolite GS-441524 .1It reduces the cytopathic effect of respiratory syncytial virus (RSV) in infected HEp-2 cells with an EC50value of 0.26 μM. 1.Mackman, R.L., Hui, H.C., Perron, M., et al.Prodrugs of a 1’-CN-4-aza-7,9-dideazaadenosine C-nucleoside leading to the discovery of remdesivir (GS-5734) as a potent inhibitor of respiratory syncytial virus with efficacy in the african green monkey model of RSVJ. Med. Chem.64(8)5001-5017(2021)

GS-441524 was shown to be a safe and effective treatment for feline infectious peritonitis (FIP). The optimum dosage was found to be 4.0 mg kg SC q24h for at least 12 weeks

GS-441524 is a potent inhibitor of feline infectious peritonitis (FIP) virus with an EC50 of 0.78 μM.. GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. GS-441524 is a molecular precursor to a pharmacologically active nucleoside triphosphate molecule. These analogs act as an alternative substrate and RNA-chain terminator of viral RNA dependent RNA polymerase. GS-441524 was non-toxic in feline cells at concentrations as high as 100 uM and effectively inhibited FIPV replication in cultured CRFK cells and in naturally infected feline peritoneal macrophages at concentrations as low as 1 uM. Note: GS-441524 is an active metabolite of Remdesivir.

E197 is a DOCK5 inhibitor. E197 can inhibit both mouse and human osteoclast activity. In particular, E197 prevented pathological bone loss in mice. Most interestingly, treatment with E197 did not affect osteoclast and osteoblast numbers and hence did not impair bone formation. E197 could represent a lead molecule to develop new antiosteoporotic drugs targeting the mechanism of osteoclast adhesion onto the bone.